BACKGROUND: Studies about associations of infections with herpes viruses and other pathogens, such as Chlamydia pneumoniae (CP) and Helicobacter pylori (HP) with cardiovascular disease (CVD), diabetes mellitus (DM), frailty and/or mortality are conflicting. Since high levels of antibodies against these pathogens occur in the elderly, the role of these pathogens in morbidity and mortality of vulnerable elderly was explored. RESULTS: Blood samples of 295 community dwelling psycho-geriatric patients were tested for IgG antibodies to herpes simplex virus type 1 and 2, varicella zoster virus, Epstein Barr virus (EBV), cytomegalovirus (CMV), human herpes virus type 6 (HHV6), CP and HP. Frailty was defined with an easy-to-use previously described frailty risk score. Relative risks (RR) with 95% confidence intervals were calculated to evaluate associations between CVD, DM, frailty and pathogens. Pathogens as a predictor for subsequent mortality were tested using Kaplan Meier analyses and Cox proportional hazard models. The mean age was 78 (SD: 6.7) years, 20% died, 44% were defined as frail, 20% had DM and 49% had CVD. Presence of CMV antibody titers was associated with frailty, as shown by using both qualitative and quantitative tests, RR ratio 1.4 (95% CI: 1.003-2.16) and RR ratio 1.5 (95% CI: 1.06-2.30), respectively. High IgG antibody titers of HHV6 and EBV were associated with DM, RR ratio 3.3 (95% CI: 1.57-6.49). None of the single or combined pathogens were significantly associated with mortality and/or CVD. CONCLUSIONS: Prior CMV infection is associated with frailty, which could be in line with the concept that CMV might have an important role in immunosenescence, while high IgG titers of HHV6 and EBV are associated with DM. No association between a high pathogen burden and morbidity and/or mortality could be demonstrated.
BACKGROUND: Studies about associations of infections with herpes viruses and other pathogens, such as Chlamydia pneumoniae (CP) and Helicobacter pylori (HP) with cardiovascular disease (CVD), diabetes mellitus (DM), frailty and/or mortality are conflicting. Since high levels of antibodies against these pathogens occur in the elderly, the role of these pathogens in morbidity and mortality of vulnerable elderly was explored. RESULTS: Blood samples of 295 community dwelling psycho-geriatric patients were tested for IgG antibodies to herpes simplex virus type 1 and 2, varicella zoster virus, Epstein Barr virus (EBV), cytomegalovirus (CMV), human herpes virus type 6 (HHV6), CP and HP. Frailty was defined with an easy-to-use previously described frailty risk score. Relative risks (RR) with 95% confidence intervals were calculated to evaluate associations between CVD, DM, frailty and pathogens. Pathogens as a predictor for subsequent mortality were tested using Kaplan Meier analyses and Cox proportional hazard models. The mean age was 78 (SD: 6.7) years, 20% died, 44% were defined as frail, 20% had DM and 49% had CVD. Presence of CMV antibody titers was associated with frailty, as shown by using both qualitative and quantitative tests, RR ratio 1.4 (95% CI: 1.003-2.16) and RR ratio 1.5 (95% CI: 1.06-2.30), respectively. High IgG antibody titers of HHV6 and EBV were associated with DM, RR ratio 3.3 (95% CI: 1.57-6.49). None of the single or combined pathogens were significantly associated with mortality and/or CVD. CONCLUSIONS:Prior CMV infection is associated with frailty, which could be in line with the concept that CMV might have an important role in immunosenescence, while high IgG titers of HHV6 and EBV are associated with DM. No association between a high pathogen burden and morbidity and/or mortality could be demonstrated.
Authors: R Schwab; P Szabo; J S Manavalan; M E Weksler; D N Posnett; C Pannetier; P Kourilsky; J Even Journal: J Immunol Date: 1997-05-01 Impact factor: 5.422
Authors: Kristine M Erlandson; Amanda A Allshouse; Eric Rapaport; Brent E Palmer; Cara C Wilson; Adriana Weinberg; Samantha MaWhinney; Thomas B Campbell Journal: AIDS Res Hum Retroviruses Date: 2015-07-08 Impact factor: 2.205
Authors: Joseph B Margolick; Jay H Bream; Otoniel Martínez-Maza; Joe Lopez; Xiuhong Li; John P Phair; Susan L Koletar; Lisa P Jacobson Journal: J Acquir Immune Defic Syndr Date: 2017-04-01 Impact factor: 3.731
Authors: Jerrald L Rector; G Neil Thomas; Victoria E Burns; Jennifer B Dowd; Raphael M Herr; Paul A Moss; Marc N Jarczok; Kristina Hoffman; Joachim E Fischer; Jos A Bosch Journal: Diabetologia Date: 2015-08-20 Impact factor: 10.122
Authors: John Joseph Heath; Neva Jennifer Fudge; Maureen Elizabeth Gallant; Michael David Grant Journal: Front Immunol Date: 2018-02-15 Impact factor: 7.561
Authors: Sarah E Jackson; George X Sedikides; Georgina Okecha; Emma L Poole; John H Sinclair; Mark R Wills Journal: Front Immunol Date: 2017-06-26 Impact factor: 7.561
Authors: Raffaella Nenna; Jing Zhai; Samuel E Packard; Amber Spangenberg; Duane L Sherrill; Fernando D Martinez; Marilyn Halonen; Stefano Guerra Journal: ERJ Open Res Date: 2020-04-27